Shire Rises After Dry Eye Disease Treatment Approval
July 12, 2016 9:51 am
Biopharmaceuticals firm Shire (SHP.L) traded higher this morning after releasing news that the U.S. Food and Drug Administration (FDA) has approved its new drug treatment Xiidra for Dry Eye Disease of which an estimated 16 Million in the US are said to suffer from.
Commenting Shire Said “An estimated 16 million adults in the U.S. are diagnosed with dry eye disease. An often chronic ocular disease, dry eye is associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment.”
Shire also stated an intention to continue to expand its ophthalmics portfolio to include treatment options for more rare diseases.
Share holders reacted positively to the news and shire is currently trading at 4962p (+3%)
Biopharmaceuticals firm Shire (SHP.L) traded higher this morning after releasing news that the U.S. Food and Drug Administration (FDA) has approved its new drug treatment Xiidra for Dry Eye Disease of which an estimated 16 Million in the US are said to suffer from.
Commenting Shire Said “An estimated 16 million adults in the U.S. are diagnosed with dry eye disease. An often chronic ocular disease, dry eye is associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment.”
Shire also stated an intention to continue to expand its ophthalmics portfolio to include treatment options for more rare diseases.
Share holders reacted positively to the news and shire is currently trading at 4962p (+3%)
Related Posts: